Kinetics of "P"-site-mediated inhibition of adenylyl cyclase and the requirements for substrate.
The kinetics of "P"-site-mediated inhibition of adenylyl cyclase was studied with the detergent-solubilized enzyme from rat brain. Mn2(+)-activated adenylyl cyclase exhibited typical noncompetitive inhibition by 2'-d3'-AMP or 2',5'-dideoxyadenosine (2',5'-ddAdo). However, enzyme that was preactivated with guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) or proteolytically with ninhibin (+ GTP gamma S) exhibited apparently uncompetitive inhibition with either 2'-d3'-AMP or 2',5'-ddAdo and with either MgATP or MgApp(NH)p (adenosine 5'-(beta gamma-imino)triphosphate) as substrate. Inhibition increased with increasing substrate concentration, consistent with distinct domains for catalysis and the P-site and the formation of a 2'-d3'-AMP.C.MgATP complex. This conclusion was supported by the kinetics of product inhibition. For both cAMP and inorganic pyrophosphate (MgPPi) inhibition was mixed, suggesting that product release is likely random sequential. Although MgPPi enhanced inhibition in the presence of P-site agonist, it did not affect the dissociation constant for P-site agonist. The uncompetitive character of P-site-mediated inhibition and the independence of inhibition by MgPPi and P-site agonist imply that the P-site binding domain is distinct from the substrate binding domain. Given the structural requirements for catalysis and for P-site-mediated inhibition, these domains would be expected to be homologous. Sensitivity to P-site-mediated inhibition was also dependent on the structure of ATP, with the following IC50 values for 2'-d3'-AMP: ATP approximately 2'-dATP (approximately 1 microM); adenosine 5'-O-(3-thiotriphosphate) (approximately 5 microM); App(NH)p (approximately 30 microM); adenosine 5'-(beta gamma-methylene)triphosphate (approximately 300 microM). The differing effectiveness of the ATP analogs to support P-site inhibition was not due to their binding at the P-site. This effect of substrate was also observed with the platelet enzyme and was independent of the means by which the enzyme was activated, whether by Mn2+ or proteolytically by ninhibin/GTP gamma S, suggesting it is a general characteristic of P-site-mediated inhibition. The data suggest a structure for activated adenylyl cyclase such that one nucleotide binding domain, selective for ATP vis-à-vis other ATP analogs, allosterically modulates a proximate P-site domain.
Johnson
R A
RA
Department of Physiology and Biophysics, State University of New York, Stony Brook 11794-8661.
Shoshani
I
I
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases / Q000302:isolation & purification; D000266:Adenylyl Imidodiphosphate / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D001792:Blood Platelets / Q000201:enzymology; D001921:Brain / Q000201:enzymology; D002462:Cell Membrane / Q000201:enzymology; D003838:Deoxyadenine Nucleotides / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008345:Manganese / Q000494:pharmacology; D051381:Rats
D000067956:Adenylyl Cyclase Inhibitors; D003838:Deoxyadenine Nucleotides; D000266:Adenylyl Imidodiphosphate; D008345:Manganese; C012873:2'-deoxy-5'-adenosine monophosphate; D000255:Adenosine Triphosphate; D000262:Adenylyl Cyclases